These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20590033)

  • 41. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.
    Rikkers L; Jenko P; Rudman D; Freides D
    Gastroenterology; 1978 Sep; 75(3):462-9. PubMed ID: 680502
    [No Abstract]   [Full Text] [Related]  

  • 42. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
    Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
    Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letter to the editor: l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Kovalic AJ; Lee TP; Da BL
    Hepatology; 2022 Nov; 76(5):E108-E109. PubMed ID: 35788964
    [No Abstract]   [Full Text] [Related]  

  • 45. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
    Rose C; Michalak A; Rao KV; Quack G; Kircheis G; Butterworth RF
    Hepatology; 1999 Sep; 30(3):636-40. PubMed ID: 10462368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simvastatin for rats with thioacetamide-induced liver failure and encephalopathy.
    Huang HC; Wang SS; Lee FY; Chan CY; Chang FY; Lin HC; Chu CJ; Chen YC; Lee SD
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e236-42. PubMed ID: 17573832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
    Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
    Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Anti-ammonemic activity of the gamma-ethyl ester of glutamic acid. Controlled clinical study].
    Santagati G; Zibetti G; Forgione F; Spaghi A
    Minerva Med; 1979 Feb; 70(8):595-603. PubMed ID: 372858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hepatic coma. Biological study].
    Plomteux G
    Ann Gastroenterol Hepatol (Paris); 1971; 7(4):341-59. PubMed ID: 5569882
    [No Abstract]   [Full Text] [Related]  

  • 50. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New approach to diagnostics and correction of portohepatic hemodynamics in patients with chronic liver diseases].
    Ermolov SIu; Shabrov AV; Ermolova TV; Ovchinnikova EV; Kolesnikov ME; Dobkes AL
    Eksp Klin Gastroenterol; 2007; (4):82-7. PubMed ID: 18409494
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.
    Michel H; Solere M; Granier P; Cauvet G; Bali JP; Pons F; Bellet-Hermann H
    Gastroenterology; 1980 Aug; 79(2):207-11. PubMed ID: 6995221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
    Butterworth RF
    Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE.
    Kircheis G
    Metab Brain Dis; 2016 Dec; 31(6):1365-1367. PubMed ID: 27838865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients.
    Zullo A; Rinaldi V; Meddi P; Hassan C; Winn S; Attili AF
    Am J Gastroenterol; 1999 Aug; 94(8):2214-8. PubMed ID: 10445552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hepatic encephalopathy: clinical aspects and pathogenesis].
    Häussinger D
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S66-7. PubMed ID: 15368172
    [No Abstract]   [Full Text] [Related]  

  • 57. [Effects of the arginine-ornithine combination on the arterial ammonia levels in chronic liver diseases and hepatic coma].
    Miszputen SJ; Ganc AJ; Costa AA; Reibscheid S; Vilela MP
    AMB Rev Assoc Med Bras; 1968 Jul; 14(7):117-22. PubMed ID: 5304250
    [No Abstract]   [Full Text] [Related]  

  • 58. Management of hepatic encephalopathy in patients with cirrhosis.
    Wright G; Jalan R
    Best Pract Res Clin Gastroenterol; 2007; 21(1):95-110. PubMed ID: 17223499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
    Ahn JO; Li Q; Lee YH; Han SM; Hwang CY; Youn HY; Chung JY
    J Vet Sci; 2016 Sep; 17(3):431-3. PubMed ID: 26726023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy.
    Mínguez B; García-Pagán JC; Bosch J; Turnes J; Alonso J; Rovira A; Córdoba J
    Hepatology; 2006 Apr; 43(4):707-14. PubMed ID: 16557541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.